Key result
The Micra leadless pacemaker demonstrated >99.0% implant success and low pericardial effusion rates across three consecutive cohorts from 2013 to 2020 despite evolving patient profiles.
Why the study?
Whether the patient population and outcomes for leadless pacemakers have changed over time across pre-market and post-market environments was not well studied.
Observational (n=3,466)
Yes
Over time, the patient profile for leadless pacemakers has shifted toward more patients precluded from transvenous pacing and more septal placements, while maintaining high implant success and low complication rates.
Answers are grounded in this paper and cite their sources.
Success and safety maintained as leadless pacing expands to complex patients; extends observational data but leaves open randomized confirmation.
Funding Acknowledgements Type of funding sources: Private company. Main funding source(s): Medtronic, Inc. OnBehalf Micra Acute Performance EMEA Investigators Background The first in-man implant of the Micra leadless pacemaker occurred in December 2013. While prior trials demonstrated a high implant success rate and favorable safety and efficacy results; whether the patient population and outcomes have changed over time is not well studied. Purpose To characterize the evolution of patient profile and outcomes for patients receiving a leadless pacemaker through the pre-market and post-market environment. Methods Patients undergoing a Micra leadless pacemaker implant attempt from the initial Micra Investigational Device Exemption [IDE] and current Micra studies (Micra post-approval registry [PAR], Micra acute performance [MAP] study) were analyzed. Patient characteristics and pericardial effusions regardless of severity were summarized. Results The 3466 patients included in the analysis underwent a Micra implant attempt and were enrolled during consecutive timeframes: patients from the Micra IDE study (n = 726) underwent a Micra implant attempt from 2013-2015, patients from the PAR (n = 1814) from 2015-2018, and patients from Micra MAP cohort (n = 926) from 2018 – 2020. Implant success was >99.0% in all 3 studies. Median age ranged from 78 – 79 years among the 3 studies without significant difference. There were more patients requiring dialysis in the MAP cohort compared to the PAR or IDE cohorts (10.3%, 7.9%, and 3.9%, respectively; P < 0.001), but fewer patients with congestive heart failure (8.3%, 13.1%, and 18.0%; P < 0.001). Pacing indication was significantly different between the studies, with fewer patients in MAP having an indication of bradyarrhythmia associated with atrial fibrillation (AF) and more having an indication associated with atrioventricular block without AF (P < 0.001). The number of patients considered to be precluded for a transvenous pacemaker implant increased significantly from the initial IDE study to the PAR and MAP studies (6.2%, 23.9%, and 44.1%, respectively, P < 0.001). Implant site placement was mostly apical for the IDE but shifted to mostly septal placement in the PAR and MAP (septal placement: 33.3%, 64.0%, and 79.5%, respectively). The rate of pericardial effusion regardless of severity was 1.79% (n = 13) in the IDE, 0.83% (n = 15) in the PAR, and 0.97% (n = 9) in MAP (figure). Mean pacing thresholds among MAP EMEA patients were low (0.61 ± 0.40V) at implant and remained stable through 12 months (0.62 +/- 0.41V). Conclusion Despite patient differences over time, the Micra leadless pacemaker was implanted with a high success rate and a low perforation rate, in-line with prior reports. Abstract Figure. Pericardial effusion rate by study
No takes yet. Share an insight, caveat, or question.
Garweg et al. (2021) conducted an observational in Bradyarrhythmia or atrioventricular block requiring pacing (n=3,466). Micra leadless pacemaker vs. Consecutive historical cohorts (IDE vs PAR vs MAP) was evaluated on Implant success and pericardial effusion. The Micra leadless pacemaker demonstrated >99.0% implant success and low pericardial effusion rates across three consecutive cohorts from 2013 to 2020 despite evolving patient profiles.
Synapse has enriched 10 related papers. Consider them for comparative context: